Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
Slovenian Journal of Public Health
Volume 60 (2021): Numero 4 (December 2021)
Accesso libero
Relationship between quality of life indicators and cardiac status indicators in chemotherapy patients
Blaž Matija Geršak
Blaž Matija Geršak
,
Andreja Kukec
Andreja Kukec
,
Henning Steen
Henning Steen
,
Moritz Montenbruck
Moritz Montenbruck
,
Maja Šoštarič
Maja Šoštarič
,
Arne Kristian Schwarz
Arne Kristian Schwarz
,
Sebastian Esch
Sebastian Esch
,
Sebastian Kelle
Sebastian Kelle
,
Sorin Giusca
Sorin Giusca
,
Grigorios Korosoglou
Grigorios Korosoglou
,
Pia Wülfing
Pia Wülfing
,
Susan Dent
Susan Dent
e
Daniel Lenihan
Daniel Lenihan
| 20 ott 2021
Slovenian Journal of Public Health
Volume 60 (2021): Numero 4 (December 2021)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Articolo
Immagini e tabelle
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Article Category:
Original scientific article
Pubblicato online:
20 ott 2021
Pagine:
199 - 209
Ricevuto:
09 mar 2021
Accettato:
31 mar 2021
DOI:
https://doi.org/10.2478/sjph-2021-0028
Parole chiave
antineoplastic agents
,
cardiotoxicity
,
ventricular function – left
,
ventricular function – right
,
quality of life
,
magnetic resonance imaging
,
cine
,
echocardiography
,
lymphoma
,
Hodgkin disease
,
breast neoplasms
© 2021 National Institute of Public Health, Slovenia, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
EQ-5D questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 2
EQ-5D questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 3
EQ-5D questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 4
SF-36 physical component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 5
SF-36 physical component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 6
SF-36 physical component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 7
SF-36 mental component questionnaire events – (A) clinical definition of cardiotoxicity; (B) clinical indication for cardioprotective therapy initiation; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 8
SF-36 mental component questionnaire events – traditional cardiac imaging modality metrics: (A) ECHO LVEF – echocardiographic left ventricular ejection fraction; (B) CMR LVEF – traditional cardiac magnetic resonance left ventricular ejection fraction; (C) MYOSTRAIN LVEF – fast strain-encoded cardiac magnetic resonance left ventricular ejection fraction; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Figure 9
SF-36 mental component questionnaire events – myocardial strain imaging modality metrics: (A) ECHO GLS – echocardiographic global longitudinal strain; (B) CMR GLS – traditional cardiac magnetic resonance global longitudinal strain; (C) MYOHEALTH, (D) FUNCTIONAL MYOSTRAIN, (E) MYOSTRAIN ≤-11 and (F) MYOSTRAIN ≤-12 – percent of left ventricle longitudinal and circumferential fast strain-encoded cardiac magnetic resonance segments with normal, functional, ≤-11% or ≤-12% strain, respectively; Germany, single-center study, August 2017 through October 2020, chemotherapy for cancer treatment.
Anteprima